<DOC>
	<DOCNO>NCT02067104</DOCNO>
	<brief_summary>This study single site double blind Phase II study evaluate chemopreventative effectiveness vismodegib treatment subject high risk develop basal cell carcinoma ( BCC ) .</brief_summary>
	<brief_title>Vismodegib Basal Cell Carcinomas ( BCC ) Chemoprevention</brief_title>
	<detailed_description>The primary objective study determine vismodegib pulse therapy significantly reduce incidence newly diagnose basal cell carcinoma ( BCC ) high risk individual compare placebo , measure incidence biopsy confirm BCC 24 month period . The secondary objective determine difference incidence newly diagnose squamous cell carcinoma ( SCC ) subject receive vismodegib treatment compare placebo , measure incidence biopsy confirm SCC 24 month period .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Signed date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect Comply schedule visit , treatment plan , laboratory test , study procedure . At least 18 year age time informed consent . History 3 biopsy confirm BCCs precede 2 year , calculate 2 year prior screen visit . No active skin cancer . Women reproductive potential must agree use two form acceptable contraception Male subject must agree use condom time , even vasectomy , sexual intercourse female partner reproductive potential treatment vismodegib 2 month last dose avoid expose pregnant partner unborn fetus vismodegib . Male patient must agree donate sperm study 2 month discontinuation vismodegib Agreement donate blood blood product study 7 month last dose . Ability understand willingness sign write informed consent document English Women pregnant lactating , plan pregnancy enrol study 7 month last dose study drug . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Subjects clinically stable chronic medical condition include , limited , controlled hypertension , diabetes mellitus type II , hypercholesterolemia , osteoarthritis , allow enter study . Inability unwillingness swallow capsule . Have history alcohol substance abuse , unless full remission great 6 month prior screen visit ( Day 0 ) consent form sign . Known infected human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C virus . Currently receive vismodegib , biologics chemotherapy Currently undergo treatment photodynamic therapy , topical chemotherapy agent include Imiquimod , fluorouracil Subjects Gorlins syndrome Subjects receive type solid organ transplant Subjects take immunosuppressive medication screen visit . ( Day 0 ) Participation study use investigational experimental therapy procedure within 4 week 5 halflives ( whichever longer ) screen visit and/or study participation . Subjects participate study investigational experimental therapy procedure time participation study . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Subjects unable unwilling comply study visit schedule requirement study Subjects unable speak read English language A subject , opinion sponsorinvestigator uncooperative unable comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>